Clinical Trials

Do you have chronic bronchitis and COPD and want to improve treatment? This study will be testing how well a medicine called ivacaftor that is used to treat cystic fibrosis works also to treat symptoms of chronic bronchitis. New research suggests chronic bronchitis may be due to a problem similar to cystic fibrosis. To participate in this study, you must be 40 to 80 years old, have a history of smoking, and have not been diagnosed with asthma or cystic fibrosis. This study will be conducted in Birmingham, Alabama.

Do you have COPD? This study will be looking for genes that may play a role in the development of COPD by looking at the blood from patients who have COPD, as well as the blood from those patients’ family members. To participate in this study, you must be 52 years old or younger and must not be pregnant or have other serious lung diseases such as lung cancer. This study will be conducted in Boston, Massachusetts.

Are you a healthy adult or someone with a history of lung infections such as pneumonia or bronchitis? This study aims to compare fluid and tissue samples from the nose and lungs of healthy adults with people who have a lung disease. Researchers hope to learn why some people are more susceptible to certain infections. This study is located at the NIH Clinical Center in Bethesda, Maryland.

Are you an adult with a diagnosed sleep phase disorder? This study aims to assess the sleep patterns and quality of sleep in people who have sleep phase disorders to determine how the disorders affect their circadian rhythms. To participate in this study, you must be at least 18 years old and have a sleep phase disorder, such as advanced sleep-wake phase syndrome or delayed sleep-wake phase syndrome. This study is located in Chicago, Illinois.

Do you have overweight? Circadian rhythm disorders can cause overweight and obesity. This study is examining how not getting enough sleep causes these complications. To participate in this study, you must be between the ages of 20 and 40 and have overweight but not obesity. This study is located in New York, New York.

Are you a healthy adult who regularly sleeps for 6.5 or fewer hours? This study is examining whether getting enough sleep can lower your risk of high blood pressure. To participate in this study, you must be between 18 and 65 years old, regularly sleep for 6.5 or fewer hours, and be able to adjust your sleep schedule for the study. This study is located in Rochester, Minnesota.

The purpose of this study is to determine the occurrence of scarring of the heart (cardiac fibrosis) and inflammation in those with perinatally acquired Human Immunodeficiency Virus (HIV) infection compared to people not infected with HIV. The information learned from this research may help the investigator to better understand the link between cardiac fibrosis and cardiac dysfunction and inflammation in those with perinatally acquired HIV infection compared to the uninfected.

The purpose of this study is to non-invasively characterize the fibrotic consequences of single ventricle physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

The purpose of this study is to determine if acquired (partial) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) deficiency contributes substantially to the pathogenic mechanisms underlying Chronic Rhinosinusitis (CRS), creating a localized environment that impairs mucociliary clearance (MCC).